摘要:
Provided is a method of preparing a cyclic olefin polymer by addition polymerization of a cyclic olefin monomer, the method including contacting a metal catalyst complex represented by Formula 1 below with a cyclic olefin monomer. [M(L1)x(Ll2)y(L3)z]a[Ani]b wherein M is a Group X metal; [M(Li)χ(L'2)y(L3)z] is a cationic complex; Li is an anionic hydrocarbyl-containing ligand; U2 is a neutral ligand; L3 is an N-heterocyclic carbene ligand; [Ani] is an anion capable of weakly coordinating with the metal M; x is 1 or 2; y is 0 to 4; z is 1 or 2;2≤x+y+z≤6; a and b are respectively the number of cations and the number of anions capable of weakly coordinating with the metal M and are each a number of 1-10 which is used to satisfy the net charge balance of the metal catalyst complex, and wherein for each of L1, L2, and L3, when a plurality of ligands are present in a molecule of the metal catalyst complex, the ligands may be the same or different. According to the method of the present invention, a high molecular weight cyclic olefin addition polymer can be produced in a high yield even when using a polar functional group-containing cyclic olefin monomer. A polymer produced using the method shows good thermal stability.
摘要:
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von Cycloalkenamer-haltigen Zusammensetzungen sowie derartige Cycloalkenamer-haltigen Zusammensetzungen. Die Erfindung betrifft weiterhin die Verwendung dieser Cycloalkenamer-haltigen Zusammensetzungen auf dem Gebiet von Verpackungsmaterialien, insbesondere für Lebensmittel.
摘要:
The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.
摘要:
The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.
摘要:
A supported catalyst for the ring-opening metathesis polymerization (ROMP) of cycloolefins, comprising the reaction product of
a) a catalyst support containing
aa) hydrophilic inorganic oxides of elements of main groups IIa, IIIa or IVa, or of subgroup IVb of the periodic table, or a mixture of said oxides, or mixed oxides of said elements, ab) aluminoxanes and optionally Al-alkyls, ac) and polyfunctional organic crosslinkers,
b) and of Schrock-type catalysts based on alkylidene- or alkylidyne-complexes of transition elements of subgroups IVb to VIII of the periodic table, a process for the preparation of said supported catalysts and a process for the ROMP of cycloolefins, wherein said supported catalysts are used.
摘要:
The present invention relates to a process for producing cycloalkenamer-containing compositions and to such cycloalkenamer-containing compositions. The invention further relates to the use of these cycloalkenamer-containing compositions in the field of packaging materials, especially for food and drink.
摘要:
The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.